AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks
AVT04 biosimilar shows consistent efficacy results in both ustekinumab-switching and ustekinumab-naïve patients, supporting its integration into real-world practice as an effective and cost-saving therapeutic option. Further studies are warranted to confirm and expand these preliminary findings across a broader bio-naïve cohort.
Authors
- Lorenzo Marcelli (ORCID: https://orcid.org/0009-0003-7635-5131)
- Edoardo Mortato (ORCID: https://orcid.org/0009-0008-3763-6922)
- Maria Rosa Ingrosso (ORCID: https://orcid.org/0000-0001-5919-2922)
- Lorenzo Tofani
- Lorenzo Savastano
- Domenico Marrapodi
- Marina Talamonti
- Valerio Gneo
- Luca Bianchi
- M. Galluzzo
Institutions
- University of Rome Tor Vergata (IT)
- Policlinico Tor Vergata (IT)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1007/s13555-026-01696-z
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00